Short Interest in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Increases By 98.7%

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 30,000 shares, a growth of 98.7% from the February 13th total of 15,100 shares. Currently, 5.4% of the company’s shares are sold short. Based on an average daily trading volume, of 362,000 shares, the short-interest ratio is currently 0.1 days.

Hedge Funds Weigh In On Bluejay Diagnostics

A hedge fund recently raised its stake in Bluejay Diagnostics stock. Anson Funds Management LP grew its position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) by 359.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 319,280 shares of the company’s stock after buying an additional 249,770 shares during the period. Anson Funds Management LP owned approximately 1.93% of Bluejay Diagnostics worth $41,000 at the end of the most recent quarter. Institutional investors and hedge funds own 18.47% of the company’s stock.

Bluejay Diagnostics Stock Up 1.5 %

Shares of BJDX stock opened at $4.04 on Friday. Bluejay Diagnostics has a 12-month low of $3.03 and a 12-month high of $349.56. The firm has a market capitalization of $2.23 million, a price-to-earnings ratio of 0.00 and a beta of 0.38. The firm has a fifty day moving average of $3.75 and a 200-day moving average of $4.85.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.